Author:
Muluneh Benyam,Conti Rena M.,Nguyen Joehl,Cole Ashley,Larson Richard A.,Dusetzina Stacie B.
Publisher
Springer International Publishing
Reference58 articles.
1. Wilkes JJ, Lyman GH, Doody DR, et al. Health care costs associated with contemporary chronic myelogenous Leukemia (CML) therapy compared to other hematologic malignancies (HEM). Blood. 2019;134(Supplement_1):4753. https://doi.org/10.1182/blood-2019-124106.
2. Dusetzina SB, Jazowski S, Cole A, Nguyen J. Sending the wrong price signal: why do some brand-name drugs cost medicare beneficiaries less than generics? Health Aff (Millwood). 2019;38(7):1188–94. https://doi.org/10.1377/hlthaff.2018.05476.
3. Cole AL, Wood WA, Muluneh B, Lund JL, Elston Lafata J, Dusetzina SB. Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib. JCO Oncol Pract. 2020;16(5):e443–55. https://doi.org/10.1200/JOP.19.00301.
4. 1 Recommendations | Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | Guidance | NICE. https://www.nice.org.uk/guidance/ta425/chapter/1-Recommendations. Accessed August 18, 2020.
5. Overview | Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | Guidance | NICE. https://www.nice.org.uk/guidance/ta576. Accessed August 18, 2020.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献